Diabetic Nephropathy
Endothelia receptor antagonist protects against diabetic nephropathy
Published in Obesity and Diabetes Week, March 14th, 2005
According to recent research from Japan, "We have investigated the protective effect of YM598, a selective endothelin type A receptor antagonist, against an endothelia-l-induced proliferation of rat mesangial cells and renal function in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, an animal model of type 2 diabetes. YM598, but not K-8794, a selective endothelin type B receptor antagonist, inhibited the endothelia-1-induced proliferation of cultured mesangial cells derived from intact Wistar rats in a concentration-dependent manner. YM598 (0.1 or 1 mg/kg), enalapril (5...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Therapy
Therapeutic potential of glucagon-like peptide-1 reviewed - Heart Attack Risk Factors
Apolipoprotein B predicts heart attack risk in metabolic syndrome - Metabolic Syndrome
New target for treatment of metabolic syndrome reported - Obesity and Diabetes
Effects of troglitazone on glucose production in hepatocytes reported - Obesity and Diabetes
Obesity and type 2 diabetes in adolescents investigated - Atherosclerosis
Amyloid A3 expression stimulated by dexamethasone and IL-6 - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
